INTRODUCTION S100 proteins are a family of small, highly homologous proteins that contain two calcium-binding EF-hand motifs (reviewed in (1) ). Because the binding of calcium ions is the most important biochemical feature of S100 proteins, they are thought to function as sensors of calcium ion concentration in the cell. They appear to have several functions, including regulation of protein phosphorylation, cytoskeleton polymerization and cell cycle progression. S100A6 (calcyclin) is a typical member of the S100 family. The function of S100A6 remains unclear, but evidence suggests that it is involved in cell cycle regulation (2, 3) and exocytosis (4, 5) . S100A6 may also be involved in tumorigenesis: the protein is overexpressed in several tumors, e.g., melanoma (6) .
Attempts to elucidate the function of S100A6 have involved the search for its calciumregulated target proteins. Several such proteins have been identified: glyceraldehyde-3-phosphate dehydrogenase (7) , annexin II (8) , annexin VI (9) , and annexin XI (10) . In 1996, a novel mouse protein was identified on the basis of its ability to interact with S100A6 in a calcium-dependent manner (11) . It was named Calcyclin-Binding Protein (CacyBP) (12) . In vitro characterization of the interaction between S100A6 and CacyBP showed that the S100A6-binding domain in CacyBP comprises 52 C-terminal residues and that the dissociation constant for the S100A6-CacyBP complex is approximately 1 µM (13). CacyBP is expressed in many tissues in mice and rats, but its highest expression level is in the brain (14). In cortical neurons, upon cell stimulation and elevation of intracellular calcium concentration, CacyBP undergoes a translocation from the cytoplasm to the perinuclear space (15) .
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CacyBP/SIP interacts with Siah-1, and the C-terminal region interacts with Skp1. Skp1 binds to Ebi, a protein that recognizes β-catenin, which is the substrate that is ubiquitinated and later degraded. β-catenin is an important oncogene involved in the development of colon cancer (17, 18) . It regulates the activity of Tcf/Lef transcription factors, which promote cell proliferation. A separate pool of β-catenin participates in adherens junctions (19) .
At the time of the discovery of CacyBP there were no homologs of this protein deposited in the sequence databases. In 1999 a novel yeast protein called Sgt1 was discovered (20) . Its human homolog is approximately 20% identical to mouse CacyBP. In yeast Sgt1 interacts with Skp1, a protein component of the SCF ubiquitin ligase and of kinetochore complexes. Some yeast Sgt1 mutants exhibit defects in chromosome segregation that result in arrest of the cell cycle at G2 phase. In other Sgt1 mutants, ubiquitination of Sic1 and Cln1 (two cell cycle regulators) is impaired, and this impairment results in cell cycle arrest at G1.
These results suggested that Sgt1 is required for normal Skp1 function in kinetochore and SCF. Recently, several papers have shown involvement of Sgt1 in R gene-mediated plant defense against pathogens (review article: (21) ). However the link between the involvement of Sgt1 in ubiquitination and pathogen response remains unclear.
The most conserved regions of CacyBP/SIP and Sgt1 are located near their C termini.
The S100A6-binding domain is located in this region of CacyBP/SIP (13) . Therefore, we determined whether human Sgt1 interacts with S100A6 and other S100 proteins and characterized this interaction. These results, together with our previous data on CacyBP/SIP (22) , suggest that S100 proteins can regulate two different ubiquitination pathways in a calcium-dependent manner. were purified from the agarose gel using QIAquick Gel Extraction Kit (QIAGEN). The appropriate vector and insert were ligated by T4 DNA ligase (Promega), and the ligation products were used to transform E. coli (TOP10F' strain). Single-colony PCR was used to detect colonies that contained the insert. The plasmids were purified and sequenced.
The plasmid pET21d-Skp1-H6 (23) was generously provided by Dr. R. Poon from Hong Kong University of Science and Technology, China. Sgt1, , and Skp1. Expression plasmids were introduced into the E. coli BL21(DE3) strain (Novagen). The bacteria were cultured in LB medium with kanamycin and expression was induced by the addition of IPTG. The bacteria were further cultured for around 3 h. The expressed His-tagged proteins were purified on Ni-NTA-agarose resin (QIAGEN) as previously described (22) . The His tag was removed by biotinylated thrombin (Novagen) cleavage according to manufacturer's instructions. The proteins were dialyzed against a desired buffered solution. Rabbit S100A6 was purified as previously described (8) . 7 µg of S100A6 was applied were mixed with 7 µg of S100A6 in the presence of 1 mM CaCl 2 or 2 mM EGTA. EDC and NHS cross-linking reagents (Sigma) were added from fresh stocks to 4 mM and 10 mM final concentration, respectively. In control reactions Sgt1 and S100A6 were cross-linked alone or both proteins were incubated without cross-linking reagents. After the reaction was carried out for 1 h at room temperature, the proteins were precipitated with acetone and analyzed on SDS-glycine-PAGE or SDS-tricine-PAGE. Fifteen percent of each reaction mixture was analyzed using Western blot with anti-S100A6 polyclonal antibody, anti-Sgt1 polyclonal antibody, or anti-His tag monoclonal antibody (HIS-1, Sigma). The blots were incubated 7 with a chemiluminescent substrate (Super Signal, Pierce) and then exposed to photographic film (Amersham Biosciences).
Expression and purification of
Competition assay. Six micrograms of His-tagged human Skp1 in buffer A (20 mM Tris-HCl, pH 7.5) with 1 mM CaCl 2 or 2 mM EGTA was applied to Sepharose alone or Sgt1-conjugated Sepharose. Parallel reactions with Sgt1-conjugated Sepharose were performed in the presence of 70 µg of S100A6 (6-fold molar excess over Skp1). The unbound fraction was collected, the resin washed, and the bound protein eluted with buffer A containing 2 mM EGTA and 0.5 M NaCl. The proteins were precipitated with TCA and analyzed by SDSglycine-PAGE.
Interaction of calcium-binding proteins with Sgt1-conjugated Sepharose.
The following calcium-binding proteins were used in the assay: parvalbumin, which was a gift from Dr. C. W. Heizmann, Zurich University, Switzerland; calbindin D 9k , a gift from Dr. S. Linse, Lund University, Sweden; S100A8, a gift from Dr. C. Kerkhoff, University of Muenster, Germany; and S100A4, a gift from Dr. R. Barraclough, University of Liverpool, Great Britain. The remaining calcium-binding proteins were S100A1, S100B, and calmodulin (each purchased from Sigma).
The binding assay was performed as in 'Affinity chromatography' section with 5 µg of each calcium-binding protein in buffer A (20 mM Tris-HCl, pH 7.5) and 1 mM CaCl 2 applied to Sgt1-conjugated Sepharose.
Co-immunoprecipitation. Human epidermal cells (HEp-2 line) were cultured in
Dulbecco's Modified Eagle's Medium supplemented with 10% foetal bovine serum, penicillin (100 units/ml) and streptomycin (100 µg/ml). 
RESULTS

Interaction between S100A6 and Sgt1
The S100A6-binding region of human CacyBP/SIP was compared with a corresponding fragment of human Sgt1 using ClustalW software (24) (Fig. 1) . In this region the amino acid identity was 29%. Because of this significant similarity between C-terminal regions of
CacyBP/SIP and Sgt1 we hypothesized that Sgt1 interacts with S100A6. To test this hypothesis, recombinant human Sgt1 with N-terminal His tag, was expressed in E. coli and purified on Ni-NTA-agarose resin. This one-step purification procedure yielded protein that was pure enough for biochemical characterization. The tag was cleaved off and Sgt1 was coupled to CNBr-activated Sepharose. Affinity chromatography was used to check whether Sgt1 could interact with S100A6 (Fig. 2) . S100A6 was applied to Sgt1-Sepharose, CacyBP/SIP-Sepharose or Sepharose alone in the presence of 1 mM CaCl 2 and bound protein was eluted in the presence of 2 mM EGTA. S100A6 was present in the fractions eluted from CacyBP/SIP-bound and Sgt1-bound resins, but not from Sepharose alone. This result shows that S100A6 interacts with Sgt1 in a calcium-dependent manner.
To confirm the interaction between human Sgt1 and S100A6, we performed chemical cross-linking experiments using EDC and NHS reagents (Fig. 3A) . As control reactions each individual protein was cross-linked alone and both proteins were incubated without EDC and NHS. The products of the reactions were analyzed by PAGE and Western blotting.
Coomassie staining of the SDS-glycine-PAGE ( A similar chemical cross-linking experiment was carried out to identify the S100A6-binding domain in Sgt1 (Fig. 3B) . First, we produced a recombinant His-tagged Sgt1 fragment that consisted of residues 263 through 333 (71 residues from C-terminus) and corresponded to the previously identified S100A6-binding domain in CacyBP/SIP. This tagged fragment has a calculated molecular weight of 10.5 kDa, but migrates in SDS-Tricine-PAGE as a band of around 13 kDa. We next subjected the protein to chemical cross-linking and analysis by PAGE. Coomassie staining revealed a band of 10 kDa corresponding to S100A6, a band of 13 kDa corresponding to His-tagged Sgt1-(263-333) and a band of 20 kDa that corresponded to a cross-linked S100A6 dimer. An additional band was seen only in the cross-linking reaction containing all components and CaCl 2 . Its apparent mass was around 10 kDa larger than that of Sgt1 fragment. The additional fragment was recognized by anti-Histag antibody and anti-S100A6 antibody, which indicated that it corresponded to a crosslinked complex of Sgt1-(263-333) and S100A6. Therefore, Sgt1-(263-333) fragment contains the S100A6-binding domain. Little of the cross-linked complex was detected when the reaction was carried out in the absence of CaCl 2 , a result confirming the calcium dependence of the binding.
The lack of influence of S100A6 on Sgt1-Skp1 binding
A prominent biochemical feature of Sgt1 is its ability to interact with Skp1 and regulate Skp1-containing SCF and kinetochore complexes (20) . Because Sgt1 also binds to S100A6, we hypothesized that S100A6 influences the Sgt1-Skp1 interaction. The S100A6-binding domain in Sgt1 is located in the C terminal region, and the Skp1-binding domain in CacyBP/SIP is also located in its C-terminal part, after residue 74 (16) . These facts suggested that the Skp1-and S100A6-binding domains in human Sgt1 might overlap. To determine whether mammalian S100A6 and Skp1 can compete in binding to Sgt1, we performed affinity chromatography. His-tagged human Skp1 was applied to a column containing either Sepharose alone or Sgt1-conjugated Sepharose. The unbound fraction and the fraction eluted with 0.5 M NaCl were collected and analyzed by electrophoresis through SDS-glycine polyacrylamide gels. Skp1 bound to Sgt1-conjugated Sepharose, but not to Sepharose alone (Fig. 4) . When Skp1 and a 6-fold molar excess of S100A6 were applied in the presence CaCl 2 to the column containing Sgt1-conjugated Sepharose, the bound fraction contained both Skp1 and S100A6. Moreover, the amount of His-tagged Skp1 that bound to Sgt1 in the presence of excess S100A6 and CaCl 2 did not differ from that bound in the absence of S100A6. This result shows that Skp1 and S100A6 do not compete in binding to Sgt1 and that the Skp1-binding domain and the S100A6-binding domain are probably separate in Sgt1.
Interaction between Sgt1 and other members of the S100 family
CacyBP/SIP interacts not only with S100A6 but also with other members of the family of highly homologous S100 proteins (22) . To study the possible interaction between Sgt1 and S100 proteins other than S100A6, we again performed affinity chromatography using Sgt1-conjugated Sepharose (Fig. 5) . Different S100 proteins (S100A1, S100A4, S100A6, S100A8, S100B, S100P, and calbindin D 9k ) and other calcium-binding proteins (parvalbumin and calmodulin) were applied individually to Sgt1-conjugated Sepharose in the presence of 1 mM CaCl 2 . Analysis of the unbound fraction and the fraction eluted by EGTA showed that Sgt1 interacts strongly with S100A6 and S100P proteins and more weakly with S100B. S100A1
and S100A4 were also present in the bound fraction, but the interaction was very weak and it might be non-specific. S100A8, calbindin D 9k , calmodulin and parvalbumin did not bind to 12
Co-immunoprecipitation of S100A6 and Sgt1
To establish whether interaction between S100A6 and Sgt1 can occur in vivo we performed co-immunoprecipitation experiments form cell extracts using monoclonal anti-S100A6 antibody. Human epidermal HEp-2 line was selected for these experiments, because it expresses both S100A6 and Sgt1. Figure 6 shows that Sgt1 was co-immunoprecipitated with S100A6 in the presence of 2 mM CaCl 2 . Sgt1 was not co-immunoprecipitated by a nonrelevant monoclonal antibody and addition of excess of recombinant CacyBP/SIP abolished the interaction, which confirms that the observed effect was specific.
S100A6 inhibits the phosphorylation of Sgt1-(263-333)
It has been previously shown that S100 proteins are able to regulate phoshporylation of their target proteins, most often by binding and blocking the phosphorylation site. Therefore, we hypothesized that the function of Sgt1-S100A6 interaction might be to regulate the phosphorylation of S100A6-binding domain of Sgt1. A search of PhosphoBase (25) revealed that in Sgt1-(263-333) serine 299 can be phosphorylated by casein kinase II. To check whether this phosphorylation can be regulated by S100A6 we performed in vitro phosphorylation assays (Fig. 7) . In these assays Sgt1-(263-333), but not S100A6, was efficiently phosphorylated by casein kinase II in the presence of 1 mM CaCl 2 . Addition of S100A6 inhibited phosphorylation of Sgt1-(263-333). In the presence of 2 mM EGTA inhibition of Sgt1 fragment phosphorylation was much weaker. The changes in Sgt1 phosphorylation were not due to the changes in the activity of the kinase because its autophosphorylation was equal in all the reactions. These results show that S100A6 can regulate the phosphorylation of Sgt1 region containing S100A6-binding domain.
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We also performed a phosphorylation assay with Sgt1-(263-333) fragment carrying a previously described E303K mutation (see Discussion). In this mutant the consensus pattern for casein kinase II site is no longer present. However E303K mutant was efficiently phosphorylated (not shown), suggesting that casein kinase II phosphorylation site is different from the one identified by computer prediction.
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DISCUSSION
In this work we showed that human Sgt1, like its homolog CacyBP/SIP, interacts in a calcium-dependent manner with S100A6 and other S100 proteins. Moreover, we determined that S100A6 binds to Sgt1-(263-333), a C-terminal fragment corresponding to the domain in CacyBP/SIP that binds to S100A6 and to other S100 proteins (22) . Therefore, we assume that this C-terminal region of Sgt1 also binds S100 proteins other than S100A6. Our results also showed that S100A6 does not regulate the interaction between Sgt1 and Skp1 through simple competition. This finding suggests that separate domains for binding to S100A6 and to Skp1 exist in Sgt1.
Interestingly, a functionally deficient yeast mutant, Sgt1-5, has a mutation (E364K) in the S100A6-binding domain identified in the present study. This mutation together with another point mutation outside the S100A6-binding domain cause defects in the ubiquitination of cell cycle regulators; however, the mutant protein retains the ability to interact with Skp1 (20) . A human CacyBP/SIP mutant modeled after Sgt1-5 that carries only a single mutation (E216K) in its S100A6-binding region acts in a dominant-negative fashion and interferes with β-catenin ubiquitination and degradation in vivo (16) . The check whether the negative effect of this point mutations stems from the fact that they abrogate the interaction between Sgt1 and S100A6 we produced recombinant Sgt1-(263-333) fragment that carried a mutation corresponding to the described above (E303K for human Sgt1). This fragment was efficiently cross-linked with S100A6, which shows that its ability to bind S100A6 was not affected. However, the properties of mutants indicate that the S100A6-binding region is essential for the function of CacyBP/SIP and Sgt1 in the ubiquitination process. When S100A6 interacts in a calcium-dependent manner with C-terminal region, the interaction is likely to regulate the activity of CacyBP/SIP and Sgt1. To search for possible mechanism of such regulation we studied the influence of S100A6 on Sgt1 phosphorylation. Several members of S100 protein family have been shown to regulate the phosphorylation of their target proteins (review articles: (1, 26) ). For example, S100A4 was shown to inhibit the phosphorylation of its target protein liprin β1 by protein kinase C and casein kinase II (27) . Our results demonstrated that S100A6-binding domain of Sgt1 can be phosphorylated by casein kinase II and that this phosphorylation is inhibited by S100A6 binding. These findings suggest that the regulation of phosphorylation might be the physiological role of Sgt1-S100A6 interaction.
In this work we demonstrated that Sgt1 is capable of interacting with several members of the S100 protein family. S100 proteins are expressed in a strictly tissue-and cell-specific fashion (28) . Therefore, the interaction between Sgt1 and S100 proteins will be regulated by the availability of S100 proteins in a given tissue and cell type.
CacyBP/SIP is a component of a novel ubiquitin ligase complex responsible for ubiquitination and degradation of β-catenin (16). Sgt1 is associated with a different ubiquitin ligase, SCF (20) . The SCF complex containing β-TrCP protein is responsible for the ubiquitination of β-catenin. However, SCF-dependent and CacyBP/SIP-dependent pathways are regulated in a different fashion. Ubiquitination by SCF requires that β-catenin is phosphorylated on serine residues (29, 30). In the CacyBP/SIP-mediated pathway, β-catenin ubiquitination is phosphorylation-independent and is triggered by the expression of Siah-1, a limiting component of the ligase complex (16) . Therefore, the two pathways are activated in different conditions and are likely to play distinct roles. Because S100A6 and some other S100 proteins can interact with CacyBP/SIP and Sgt1, these S100 proteins could regulate both pathways in a similar fashion. The defects in ubiquitination and degradation of β-catenin are key events in the development of colon cancer. It has been shown that S100A6 may be involved in the progression of colon carcinoma (31, 32, 33) . by guest on November 15, 2017 
